Skip to Content

New Drug Approvals Archive - April 2002

April 2002

Faslodex (fulvestrant) Injection

Date of Approval: April 25, 2002
Company: AstraZeneca
Treatment for: Breast Cancer

Faslodex (fulvestrant) is an estrogen receptor antagonist indicated for the treatment of hormone receptor positive metastatic breast cancer.

New Drug Approvals Archive

More News Resources

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.